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ACKGROUND & AIMS: Bariatric surgery has been
hown to reverse type 2 diabetes; however, mechanisms
y which this occurs remain undefined. Ileal interposi-
ion (IT) is a surgical model that isolates the effects of
ncreasing delivery of unabsorbed nutrients to the lower
astrointestinal tract. In this study we investigated effects
f IT surgery on glucose tolerance and diabetes onset in
CD-T2DM (University of California at Davis type 2
iabetes mellitus) rats, a polygenic obese animal model of
ype 2 diabetes. METHODS: IT or sham surgery was
erformed on 4-month-old male UCD-T2DM rats. All
nimals underwent oral glucose tolerance testing
OGTT). A subset was killed 2 months after surgery for
issue analyses. The remainder was followed until diabe-
es onset and underwent oral fat tolerance testing
OFTT). RESULTS: IT surgery delayed diabetes onset by
20  49 days compared with sham surgery (P  .05)
ithout a difference in body weight. During OGTT, IT-
perated animals exhibited lower plasma glucose excur-
ions (P  .05), improved early insulin secretion (P 
01), and 3-fold larger plasma glucagon-like peptide-
(7–36) (GLP-17–36) excursions (P  .001), and no differ-
nce in glucose-dependent insulinotropic polypeptide re-
ponses compared with sham-operated animals. Total
lasma peptide YY (PYY) excursions during OFTT were
-fold larger in IT-operated animals (P  .01). IT-oper-
ted animals exhibited lower adiposity (P  .05), smaller
dipocyte size (P .05), 25% less ectopic lipid deposition,
ower circulating lipids, and greater pancreatic insulin
ontent compared with sham-operated animals (P .05).
ONCLUSIONS: IT surgery delays the onset of dia-
etes in UCD-T2DM rats which may be related to
ncreased nutrient-stimulated secretion of GLP-17–36
nd PYY and improvements of insulin sensitivity,
-cell function, and lipid metabolism.
eywords: Bariatric Surgery; Diabetes Prevention; Gluca-
on-Like Peptide-1; Peptide-YY.ariatric surgery, such as Roux-en-Y gastric bypass
(RYGB), is currently the most effective long-term
reatment of obesity1,2 and has been shown to markedly
mprove glucose homeostasis3–5; however, the mecha-
isms by which this occurs remain undefined. The im-
rovement of glucose homeostasis after bariatric surgery
as been attributed to weight loss resulting from a re-
uction in gastric volume and/or reduced nutrient ab-
orption, depending on the type of surgery. However,
bservations made in a number of clinical studies support
key role for endocrine changes in the reversal of type 2
iabetes after bariatric surgery. First, in patients with type 2
iabetes undergoing bariatric surgery, such as RYGB, glu-
ose normalization often occurs before substantial weight
oss.5,6 Second, bariatric surgeries involving bypass of the
roximal small intestine and/or biliopancreatic diversion
re often more effective at improving obesity and reversing
ype 2 diabetes than bariatric surgeries involving only gas-
ric restriction.5,7
These observations have lead to the development of
he “hindgut” hypothesis that postulates that increased
ux of unabsorbed nutrients in the distal small intestine
esults in the activation of a neuroendocrine negative
eedback mechanism, often termed the “ileal brake,”
hich involves increased secretion of peptides, including
lucagon-like peptide-1 (GLP-1) and peptide YY (PYY)
rom L cells located in the distal gastrointestinal tract.8
ncreased secretion of these hormones may contribute to
eight loss and improved glucose metabolism.8 GLP-17–36
active form) acts to potentiate glucose-induced insulin
ecretion, inhibit glucagon secretion, decrease food in-
ake, improve insulin sensitivity, and may also promote
Abbreviations used in this paper: ANOVA, analysis of variance; AUC,
rea under the curve; GIP, glucose-dependent insulinotropic polypep-
ide; GLP-1, glucagon-like peptide-1; GLP-1R, glucagon-like peptide-1
eceptor; IT, ileal interposition; NPY2R, neuropeptide Y receptor type 2;
GTT, oral glucose tolerance test; PCR, polymerase chain reaction;
YY, peptide YY; RIA, radioimmunoassay; RM, repeated measures;
YGB, Roux-en-Y gastric bypass; TG, triglycerides; UCD-T2DM, Univer-
ity of California at Davis type 2 diabetes mellitus.
© 2010 by the AGA Institute
0016-5085/$36.00doi:10.1053/j.gastro.2010.03.005
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2438 CUMMINGS ET AL GASTROENTEROLOGY Vol. 138, No. 7-cell proliferation.9 PYY3–36 (active form) acts to inhibit
ood intake and slow gastric motility and thus maintains
eight loss.10,11 Furthermore, elevations of these hor-
ones after bariatric surgery have been reported in a
umber of clinical studies.7,12
RYGB surgery results in increased delivery of unab-
orbed nutrients to the distal small intestine, but it also
nvolves gastric restriction and bypass of the duodenum.
leal interposition (IT) is a surgical procedure in which a
egment of ileum is inserted into the proximal small
ntestine and provides a surgical model whereby the ef-
ect of RYGB surgery to increase the flux of unabsorbed
utrients to the distal gastrointestinal tract can be iso-
ated from gastric restriction and duodenal bypass. IT
urgery has been shown to induce weight loss and im-
rove insulin signaling in obese and diabetic animal
odels.13–16 The only diabetic animal models tested to
ate are the Goto-kakizaki rat and streptozotocin-treated
ong–Evans rats, both of which show diabetes with a
athophysiology unlike that observed in clinical type 2
iabetes. Goto-kakizaki rats are not obese and insulin
esistant.14 Thus, diabetes in this model depends on im-
aired islet function, making the pathophysiology of
iabetes in these animals more similar to type 1 diabetes.
imilarly, streptozotocin-treated rats are considered to be
model of type 1 diabetes because hyperglycemia is the
esult of chemically induced -cell destruction. In this
tudy we investigated the effects of IT surgery on diabetes
nset, glucose tolerance, and several biochemical param-
ters in University of California at Davis type 2 diabetes
ellitus (UCD-T2DM) rats, a model of type 2 diabetes
ombining polygenic adult-onset obesity and insulin re-
istance with -cell dysfunction.17
Materials and Methods
Diets and Animals
Male UCD-T2DM rats were individually housed
n hanging wire cages in the animal facility in the De-
artment of Nutrition at the University of California,
avis, and maintained on a 12:12-hour light-dark cycle.
t 4 months of age rats underwent sham or IT surgery.
nimals were followed until at least 1 year of age to
etermine the time to diabetes onset (long-term group)
r were killed 2 months after surgery for tissue collection
short-term group). All animals enrolled in the study
fter successful surgeries completed the study. Baseline
ody weights, measured on the day of surgery, in the
ong-term groups were 585  11 g and 594  18 g in
ham (n  9) and IT-operated animals (n  8), respec-
ively. Baseline body weights in the short-term groups
ere 598  13 g and 601  13 g in sham (n  10) and
T-operated animals (n  10), respectively. All animals
eceived ground chow (no. 5012; Ralston Purina, Bel-
ont, CA). Food intake and body weight were measured
times a week. Nonfasting blood glucose was measured beekly with a glucose meter (One-Touch Ultra; LifeScan,
ilpitas, CA) at 2:00–3:00 PM. Diabetes onset was defined
s a nonfasted blood glucose value 11.1 mmol/L (200
g/dL) on 2 consecutive weeks. The experimental proto-
ols were approved by the University of California Davis
nstitutional Animal Care and Use Committee.
IT Surgery
IT surgery was performed as described by Koop-
ans and Sclafani.18 Rats were placed on a liquid diet
Boost; Novartis, Minneapolis, MN) 3 days before surgery
nd for 5–7 days after surgery and received enrofloxacin
10 mg/kg subcutaneously) before and after surgery. An-
sthesia was induced and maintained with isoflurane
2%–5%). A midline abdominal incision was made and a
0-cm segment of ileum 5–10 cm proximal to the ileoce-
al valve was isolated and transected. An anastomosis was
ade with the remaining ends of the ileum with the use
f 7-0 silk suture (Ethicon). Next, a transection was made
–10 cm distal to the ligament of Treitz. The isolated ileal
egment was then inserted isoperistaltically. The trans-
osed segment remained innervated and with its vascu-
ature intact.
Sham-operated animals were treated in the same manner
s the IT group. Sham surgeries were performed by making
ransections in the same locations as in the IT-operated
nimals, but bowel segments were reattached by anastomo-
is in their original position. The intestines remained their
riginal length in both surgeries, but were reorganized with
espect to which intestinal segments were exposed to in-
oming nutrients only with the IT surgery.
Oral Glucose and Oral Fat Tolerance Tests
One month after surgery, an oral glucose tolerance
est (OGTT) was performed on animals from the short-term
nd long-term groups. Animals were deprived of food over-
ight and then received a 50% dextrose solution (1 g/kg of
ody weight) by oral gavage. Blood was collected from the
ail for measurement of glucose and insulin concentrations.
second aliquot of blood was placed in tubes containing
DTA, aprotinin, and a dipeptidyl peptidase IV inhibitor
nd analyzed for GLP-17–36 and total glucose-dependent
nsulinotropic polypeptide (GIP). Serum glucose was mea-
ured with an enzymatic colorimetric assay for glucose
Thermo DMA, Louisville, CO). Serum insulin, plasma
LP-17–36, and total GIP were measured by rodent/rat spe-
ific enzyme-linked immunoabsorbent assays (Millipore, St
harles, MO). The 3 sham-operated animals that developed
iabetes by 1 month after surgery were excluded from this
ata set to avoid potential confounding effects of hypergly-
emia (no IT-operated animals had developed diabetes by
his time point).
At 3.5 months after surgery, a subset of animals in the
ong-term study groups was deprived of food overnight
nd received Intralipid (Fresenius Kabi, Uppsala, Sweden)
y oral gavage (1.5 g/kg of body weight of a 20% solu-
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June 2010 IT SURGERY DELAYS TYPE 2 DIABETES ONSET 2439ion). Blood was collected from the tail into tubes con-
aining EDTA and aprotinin. Total PYY was measured by
at/mouse specific radioimmunoassay (RIA; Millipore).
Monthly Fasted Hormone and Metabolite
Profiles
Baseline and monthly blood samples were collected
fter an 8-hour fast from rats in the long-term groups into
DTA-treated tubes. Plasma was assayed for glucose, insu-
in, triglycerides (TG), cholesterol, leptin, adiponectin, and
hrelin. Fasting plasma samples were also collected from
nimals in the short-term groups on the day of killing, and
ile acids were measured with the use of the Total Bile Acids
ssay (Enzyme Cycling Method) kit (Diazyme, San Diego,
A). Plasma glucose, cholesterol, and TG were measured
ith the use of enzymatic colorimetric assays (Thermo
MA, Louisville, CO; L-type TG H kit, Wako Chemicals
SA, Inc, Richmond, VA). Insulin, leptin, and adiponectin
ere measured with rodent/rat specific RIAs (rat leptin,
ouse adiponectin; Millipore).
Tissue Collection, Tissue TG Content, and
Adipocyte Size Determination
Two months after surgery, animals in the short-
erm groups were killed with an overdose of pentobarbi-
al (200 mg/kg intraperitoneally) after an overnight fast.
issues were weighed and flash frozen in liquid nitrogen
nd stored at 80°C. Liver, skeletal muscle, and adipose
G content were measured with the use of the method of
olch et al19 for lipid extraction followed by spectropho-
ometric measurement of TG content (Thermo Electron).
Mesenteric adipocytes were isolated according to the
ethod of Rodbell20 as modified by Mueller et al.21 Packed
dipocytes (25 L) were added to an Accuvette containing
0 mL of Isoton (Beckman Coulter, Fullerton, CA). The
ccuvette was quickly placed on the sampling platform of
he MultiSizer III and a 0.5-mL aliquot was counted and
ized through a 280-m aperture. With the use of the
ultisizer 3.51 software, cells were counted and sorted into
00 size bins in a range of 12–1200 pL. The percentage of
otal adipocyte volume was calculated for each bin, and the
aximum value was reported as the peak value.
Ileal Preproglucagon and PYY mRNA
Expression
Ileal (100 mg) samples were taken from the center
f the transected segment and placed in a stabilization
olution (1XTransPrep, nucleic acid purification lysis
uffer; Applied Biosystems, Foster City, CA). Proteinase
and beads (SpexCertiprep, Metuchen, NJ) were added,
nd samples were homogenized in a GenoGrinder 2000
SpexCertiprep). Total RNAwas extracted with a 6100 Nucleic
cid PrepStation (Applied Biosystems). The Quantitect reverse
ranscriptase kit (QIAGEN, Valencia, CA) was used to DNase
reat samples and generate cDNA. The probe and primers for
reproglucagon (NM_012707, Rn01460420_g1) and PYY iNM_001034080, Rn 00562293_m1) and -2 microglobu-
in (NM_012512, Rn00560865_m1) were purchased from
pplied Biosystems (Foster City, CA). Each polymerase
hain reaction (PCR) reaction contained a final concentra-
ion of 400 nmol/L for each primer and 80 nmol/L for the
aqMan probe and commercially available PCR Mastermix
TaqMan Universal PCR Mastermix; Applied Biosystems).
he samples were amplified in an automated fluorometer
7900 HT FAST Real-Time PCR System; ABI). Final quan-
ification was done with the use of the comparative Ct
ethod (User Bulletin no. 2; Applied Biosystems) and is
eported as relative transcription to the sham-operated
roup after using -2 microglobulin to normalize the Ct
alues of target genes.
Nodose Ganglion GLP-1 Receptor and Y2R
Protein Expression
Nodose ganglia were homogenized on ice in lysis
uffer and cocktail inhibitors (3.03 g of Tris base and 12.7
L of 0.5 mol/L EDTA dissolved in 500 mL of ddH2O at
H 7.5; 1% Triton X-100, 1% antiphosphatase, 1% protease
nhibitor, 2.87 l/0.5 mL phenylmethanesulfonyl fluoride),
entrifuged, and supernatant was collected. Protein concen-
ration was determined with the use of the Bradford
ethod (Bio-Rad, Hercules, CA). Protein (65 g) was sepa-
ated by electrophoresis and transferred to nitrocellulose
embranes. Membranes were probed for GLP-1 receptor
GLP-1R) and neuropeptide Y receptor type 2 (NPY2R) with
abbit polyclonal anti–GLP-1R (Abcam, Cambridge, MA),
oat anti–mouse NPY2R (United States Biological, Swamp-
cott, MA), and rabbit anti–glyceraldehyde phosphate
ehydrogenase (Cell Signaling Technology, Danvers, MA).
ntibiotin horseradish peroxidase and goat anti–rabbit
orseradish peroxidase (Cell Signaling Technology) were
sed as secondary antibodies. Immunoblotted proteins were
etected by chemiluminescence with the use of 20 Lumi-
LO and 20 Peroxide reagents (Cell Signaling Technol-
gy). Optical densitometry of immunoreactive bands was
easured with the use of Image Quant Version 5.1 (Molec-
lar Dynamics, Piscataway, NJ).
Islet Immunohistochemistry and Pancreatic
Insulin Content
Pancreas samples were collected and immuno-
tained as previously described.17
Pancreatic insulin was extracted with a combination of
ethods by Davidson and Haist,22 Dixit et al,23 and Karam,
nd Grodsky.24 Insulin was extracted from preweighed pan-
reas samples by mincing, sonicating, and then incubating
amples overnight at 4°C in acid alcohol with aprotinin.
amples were centrifuged, the supernatant was collected,
nd the pellet was washed once more with the same solu-
ion. An alcohol diethyl ether solution (38% alcohol, 62%
ther) was added to the supernatants and incubated over-
ight at 4°C. Samples were centrifuged, and the pellet was
econstituted in 0.01N hydrochloric acid and assayed for
nsulin content by RIA (Millipore).
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2440 CUMMINGS ET AL GASTROENTEROLOGY Vol. 138, No. 7Statistics and Data Analysis
Data are presented as mean  standard error of
he mean. All statistical analyses were performed with
raphPad Prism 4.00 for Windows (GraphPad Software,
an Diego, CA) except for 3-factor analysis of variances
ANOVAs) that were performed with SAS 9.1 (SAS Insti-
ute, Cary, NC). OGTT and oral fat tolerance test (OFTT)
ata were compared by 2-factor (time  treatment) re-
eated measures (RM) ANOVA followed by post hoc
nalysis with Bonferroni’s multiple comparison test. Ab-
olute changes of body weight, food intake, and monthly
irculating hormone and metabolite data were analyzed
y mixed procedures 3-factor (time, treatment, disease-
ree days) RM ANOVA. Animals were divided into tertiles,
ased on disease-free days after surgery: 0–205, 206–250,
251 days. The incidence of diabetes was analyzed by
og-rank testing of Kaplan–Meier survival curves. The age
f diabetes onset, tissue weights, tissue TG content, ileal
RNA levels, and nodose ganglia protein levels were
nalyzed by the Student’s t test. Differences were consid-
red significant at P  .05.
igure 1. Kaplan–Meier analysis of diabetes incidence in sham-operated
lasma glucose concentrations (B), food intake (C), and body weight (D) in s
y mixed procedures 3-factor (time, treatment, and disease-free days) RM ANOResults
IT Surgery Delays the Onset of Diabetes
Without Reducing Body Weight
IT surgery delayed the onset of type 2 diabetes by
20  49 days compared with sham-operated animals
average age of onset, 265  19 days for the sham group;
85  49 days for the IT group; P  .05). IT surgery also
educed the incidence of diabetes such that by 1 year of
ge 78% of sham-operated animals were diabetic, whereas
nly 38% of IT-operated animals were diabetic (Figure
A) (P  .05). This delay in onset was clearly reflected in
onthly fasting plasma glucose concentrations that were
4%  8% higher in sham-operated animals at 8 months
fter surgery (P  .05; Figure 1B).
Food intake remained similar between sham- and IT-
perated animals during the first 5 months after surgery
Figure 1C) when diabetes incidence was low. Six months
fter surgery food intake began to increase in sham-
perated animals due to increased incidence of diabetes
nd development of diabetic hyperphagia (disease-free
9) and IT-operated (n 8) animals (A). *P .05 by log-rank test. Fasting
operated (n 9) and IT-operated (n 8) animals. *P .05 disease time(n
ham-VA. Values are expressed as mean standard error of the mean.
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June 2010 IT SURGERY DELAYS TYPE 2 DIABETES ONSET 2441ays  time, P  .05; 3-factor RM ANOVA) but not an
ffect of treatment (treatment  time, P  .20; 3-factor
M ANOVA). Body weight was similar between groups
ntil 6 months after surgery when sham-operated ani-
als began to lose weight due to increased incidence of
iabetes (disease-free days  time, P  .05; 3-factor RM
NOVA) but not an effect of treatment (treatment 
ime, P  .11; 3-factor RM ANOVA; Figure 1D).
IT Surgery Improves Glucose Tolerance and
Insulin Secretion and Increases Nutrient-
Stimulated GLP-1 and PYY Secretion
Glucose excursions in response to oral glucose ad-
inistration were lower in prediabetic IT-operated animals
han in prediabetic sham-operated animals (glucose area
nder the curve [AUC]: sham, 1587  96 mmol/L  180
inutes; IT, 1324  53 mmol/L  180 minutes; P  .05;
igure 2A). Fasting serum insulin concentrations were
5% 5% lower (P .01), and the insulin AUC was 34%
% lower in IT-operated than in sham-operated animals
insulin AUC: sham, 74,423 7359 pmol/L 180minutes;
T, 49,128  3352 pmol/L  180 minutes; P  .01; Figure
B). Furthermore, the percentage increase of plasma insulin
igure 2. Serum glucose (A), serum
nsulin (B), plasma GLP-17–36, (C) and
lasma GIP (D) concentrations after
n oral glucose gavage (1 g/kg of
ody weight, 50% dextrose solution)
n sham- (n  15) and IT-operated
n  18) animals at 1 month after sur-
ery. ***P  .0001, **P  .001 by
-factor (time  treatment) ANOVA;
P  .05, **P  .01, ***P  .001 by
onferroni’s posttest. Ileal preproglu-
agon mRNA expression 2 months af-
er surgery in sham- (n  10) and IT-
perated (n  7) animals (E). Values
re expressed as mean  standard
rror of the mean.oncentrations from baseline to 30 minutes after glucose
dministration was 314% 26% in IT-operated animals and
01% 13% in sham-operated animals (P .01), indicating
mprovement of glucose-stimulated insulin secretion with
T surgery. Peak GLP-17–36 secretion was 3-fold higher in
T-operated animals than in sham-operated animals (GLP-
7–36 AUC: sham, 16620 pmol/L 60 minutes; IT, 361
0 pmol/L  60 minutes; P  .001; Figure 2C). However,
leal preproglucagonmRNA levels at 2 months after surgery
id not differ between groups (Figure 2E). Circulating GIP
oncentrations did not differ between groups (GIP AUC:
ham, 2740  148 pmol/L  60 minutes; IT, 2347  105
mol/L  60 minutes; Figure 2D).
Peak PYY excursions in response to an oral lipid load
ere 3-fold higher in IT-operated animals than in sham-
perated animals (PYY AUC: sham, 14,264  2572 pg/mL
180 minutes, IT, 36,895  6011 pg/mL  180 minutes;
 .01; Figure 3A). Furthermore, fasting plasma PYY
oncentrations were 8-fold higher in IT-operated animals
han in sham-operated animals (P  .05). Ileal PYY
RNA content was 2-fold higher in IT-operated animals
han in sham-operated animals (Figure 3B).
1
t
a
s
2
(
i
i
F
h
(
c
a
s
3
F
(
s
(
I
I
e
T
B
E
R
S
M
T
H
K
L
L
S
I
M
P
N
*
B
A
SIC
–
A
LIM
EN
TA
R
Y
TR
A
C
T
2442 CUMMINGS ET AL GASTROENTEROLOGY Vol. 138, No. 7In contrast to the observed changes in postprandial GLP-
7–36 and PYY secretion, GLP-1R and NPY2R protein con-
ent in the nodose ganglion did not differ between sham-
nd IT-operated animals (Supplementary Figure 1).
igure 3. Plasma total PYY concentrations after an oral intralipid gavage
1.5 g/kg of body weight, 20% lipid solution) at 3.5 months after surgery in
ham- (n  7) and IT-operated (n  7) animals (A). *P  .05 by 2-factor
time treatment) ANOVA; *P  .05, **P  .01 by Bonferroni’s posttest.
leal PYY mRNA expression 2 months after surgery in sham- (n 10) and
T-operated (n  7) animals (B). *P  .05 by Student’s t test. Values are
xpressed as mean standard error of the mean.IT Surgery Improves Islet Structure and
Increases Pancreatic Insulin Content
Figure 4 shows representative images of pancreas
ections from prediabetic IT- and sham-operated animals
months after surgery. Islets from IT-operated animals
Figure 4B, D, and F) appeared more densely stained for
nsulin with better preservation of islet architecture than
slets from sham-operated animals (Figure 4A, C, and E).
urthermore, pancreatic insulin content was 2.5-fold
igher in IT- than in sham-operated animals (P  .05)
Table 1).
IT Surgery Improves Circulating Lipids and
Insulin but Does Not Affect Adiponectin
Fasting plasma TG concentrations were signifi-
antly lower in IT-operated animals than in sham-oper-
ted animals due to increased diabetes incidence in the
ham-operated group (disease-free days  time, P  .01;
-factor RM ANOVA) and possibly due to an effect of
Figure 4. Representative images of
pancreas sections from prediabetic
sham- and IT-operated animals at 2
months after surgery. H&E stain of pan-
creas sections from sham-operated (A)
and IT-operated (D) animals. Anti-insulin
immunostaining of pancreas sections
from sham-operated (B) and IT-oper-
ated (E) animals. Antiglucagon immuno-
staining of pancreas sections from
able 1. Tissue Weights, Tissue TG Content, and
Pancreatic Insulin Content
Sham (n  10) IT (n  10)
ody weight, (g) 626  19 599  19
pididymal fat depots (g) 8.9  0.5 6.7  0.8*
etroperitoneal fat depots (g) 12.0 0.8 8.8  1.2*
ubcutaneous depot (g) 45  4 38 4
esenteric depot (g) 9.9  0.5 8.6  0.8
otal white adipose tissue (g) 76  5 62 7
eart (g) 1.5  0.1 1.5  0.1
idney (g) 1.8  0.1 1.7  0.1
iver (g) 21  1 20 1
iver TG content (mg/g) 28  2 21 3*
keletal muscle TG content (mg/g) 5.0 0.7 3.7  0.3*
nguinal TG content (%) 67  2 66 3
esenteric TG content (%) 66  3 54 5*
ancreatic insulin content (g/g) 5.8  1.7 14.2  4.1*
OTE. Values are mean  standard error of the mean.
P  .05 compared with sham by Student’s t test.sham- (C) and IT-operated (F) animals.
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NOVA) (Figure 5A). Fasting plasma cholesterol concen-
rations were significantly lower in IT-operated than in
ham-operated animals due to an effect of treatment
treatment  time, P  .05; 3-factor RM ANOVA) and
ot an effect of diabetes incidence (disease-free days 
ime, P  .17; 3-factor RM ANOVA) (Figure 5B). Fasting
lasma bile acid concentrations were 2 times higher in
T-operated than in sham-operated animals at 2 months
fter surgery (P  .05) (Figure 5C).
Fasting plasma insulin concentrations remained stable
n the IT-operated group, whereas fasting plasma insulin
oncentrations decreased starting at 5 months after sur-
ery in the sham-operated animals due to both an effect
f treatment (treatment  time, P  .001; 3-factor RM
NOVA) and diabetes incidence (disease-free days 
ime, P .001; 3-factor RM ANOVA) (Figure 5D). Fasting
lasma adiponectin concentrations did not differ be-
ween groups (Figure 5E). Plasma leptin concentrations
ere significantly lower in IT-operated than in sham-
perated animals due to an effect of diabetes incidence
igure 5. Monthly measurements of
asting plasma TG (A), cholesterol (B),
nsulin (D), adiponectin (E), and leptin
F) concentrations in sham- (n  9)
nd IT-operated (n 8) animals. P
05, P  .001 treatment  time;
P  .05, **P  .01, ***P  .001 dis-
ase  time by mixed procedures
-factor (time, treatment, and dis-
ase-free days) RM ANOVA. Fasting
lasma bile acids at 2 months after
urgery in sham- (n  10) and IT-op-
rated (n  10) animals (C). *P  .05
y Student’s t test. Values are ex-
ressed as mean  standard error of
he mean.disease-free days  time, P  .05; 3-factor RM ANOVA) eut not an effect of treatment (treatment  time, P 
41; 3-factor RM ANOVA) (Figure 5F).
IT Surgery Decreases Adipocyte Size and
Tissue TG Content
Despite comparable body weight at 2 months
fter surgery, IT-operated animals had smaller epididy-
al and retroperitoneal adipose depots than did sham-
perated animals (P  .05) (Table 1). Peak mesenteric
Figure 6A and B) and subcutaneous (Figure 6C and D)
dipocyte volumes were 35% smaller in IT-operated
nimals than in sham-operated animals (P  .05). Mes-
nteric fat depot and liver and skeletal muscle TG con-
ent were all 25% lower in IT-operated animals than in
ham-operated animals (P  .05) (Table 1).
Discussion
In the present study we investigated the effects of
T surgery to delay the onset of type 2 diabetes in UCD-
2DM rats. This is the first study to investigate the
fficacy of IT surgery to delay the development of type 2
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2444 CUMMINGS ET AL GASTROENTEROLOGY Vol. 138, No. 7iabetes. Given the reproducible effects of bariatric sur-
ery to normalize glucose homeostasis and given the
ncreasing prevalence of type 2 diabetes, the effects and
echanisms of different types of bariatric surgery to
elay or prevent the development of type 2 diabetes
hould be investigated for the potential identification of
ew therapies for diabetes. In this study, IT surgery mark-
dly delayed the onset of type 2 diabetes compared with
ham surgery. The similar body weights in sham- and IT-
perated animals provide support for the hypothesis that
urgery-induced changes of endocrine function are likely to
ave an important role in the delay of diabetes onset, inde-
endent of differences in body weight. The observation
hat increases of nutrient-stimulated GLP-17–36 and PYY
ecretion in IT-operated animals did not result in de-
reased food intake brings into question the role of
ndogenous GLP-1 and PYY in the regulation of food
ntake and suggests that postoperative increases of these
ormones may not be responsible for the weight loss
bserved after bariatric surgeries, such as RYGB. How-
ver, the increases of nutrient-stimulated GLP-17–36 secre-
ion may have contributed to the observed improvements
f islet function, insulin sensitivity, and lipid metabolism
n IT-operated rats compared with sham-operated rats.
Increases of GLP-1 may have improved islet function
y increasing islet glucose sensitivity and insulin secretory
apacity. GLP-1 has been shown to not only potentiate
lucose-stimulated insulin secretion but also to increase
nsulin synthesis, stimulate -cell proliferation, and prevent
-cell apoptosis.9,25 Improvement of glucose-stimulated in-
ulin secretion was clearly shown at 1 month after surgery
uring the OGTT in which IT-operated animals exhibited
-fold greater glucose-stimulated insulin secretion than did iham-operated animals. Furthermore, IT-operated animals
ad 2.5-fold greater pancreatic insulin content than did
ham-operated animals.
IT-operated animals also exhibited improved insulin
ensitivity compared with sham-operated animals, based
n decreased fasting plasma insulin concentrations and
he lower glucose and insulin excursions during the
GTT. Increases of GLP-1 may have improved insulin
ensitivity by reducing glucotoxicity and lipotoxicity.26
LP-1 reduces glucotoxicity by improving islet function
nd insulin sensitivity and by reducing hepatic glucone-
genesis.9,27 GLP-1 may contribute to reductions in lipo-
oxicity by stimulating fat oxidation during meals.28
hus, increases of nutrient-stimulated GLP-17–36 release
ay have contributed to a reduction in adipocyte size in
T-operated animals compared with sham-operated ani-
als by increasing lipolysis in fat cells during meals.29
his decrease of adipocyte size may have contributed to
ower ectopic and circulating TG concentrations in IT-
perated animals, thereby contributing to improved in-
ulin sensitivity. Larger adipocytes, especially in the mes-
nteric adipose depot, have been shown to be more
nsulin resistant30 and therefore less sensitive to the
ntilipolytic actions of insulin, resulting in greater free
atty acid secretion into the portal vein and TG accumu-
ation in the liver.31 TG deposition in the liver is consid-
red a major contributor to hepatic insulin resistance32,33
nd also promotes increased circulating TG, resulting in
reater TG deposition in peripheral tissues,34 further
xacerbating systemic insulin resistance,32 and possibly
slet lipotoxicity.35
Changes of bile acids, which are increased after RYGB
Figure 6. Mesenteric (A) and subcu-
taneous cell (C) volume distribution
and mesenteric (B) and subcutaneous
(D) peak cell volume. *P .05, ***P
.001 by Student’s t test. Values are
expressed as mean  standard error
of the mean.n human beings36 and IT surgery in rodents,15,37 may
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June 2010 IT SURGERY DELAYS TYPE 2 DIABETES ONSET 2445epresent another mechanism by which bariatric surgery
eads to improved insulin sensitivity and resolution of
iabetes. Interposition of the ileum proximally may in-
rease absorptive capacity of the intestinal epithelium,
esulting in greater bile acid reabsorption. Bile acids have
een shown to increase energy expenditure, improve cir-
ulating lipid profiles and glucose homeostasis, and stim-
late GLP-1 and PYY secretion.38–41 Furthermore, simply
iverting the common bile duct to the distal small intes-
ine in streptozotocin-treated rats has been reported to
ompletely resolve diabetes.42 Thus, postoperative in-
reases of bile acids may have contributed to the increases
f circulating GLP-17–36 and PYY concentrations and the
ecreases of circulating TG and cholesterol concentra-
ions.
Unlike some previous studies of IT surgery in rats,13,16
leal preproglucagon mRNA levels were not elevated in IT-
perated animals, suggesting that increases of circulating
LP-17–36 concentrations after IT surgery in UCD-T2DM
ats are primarily due to increased secretion. Similar to
reviously reported data,16 the increase of nutrient-stimu-
ated PYY secretion was accompanied by an increase of ileal
YY mRNA expression. Thus, increases of plasma PYY con-
entrations were probably due to increased synthesis and
ecretion.
As expected, GIP secretion did not differ between IT-
nd sham-operated animals because the position of the
uodenum remained unchanged after both surgeries.
his is in contrast to results obtained after RYGB, in
hich GIP secretion is often decreased, probably because
f the surgical exclusion of the duodenum from contact
ith ingested nutrients.7,12 Decreases of GIP have been
roposed to contribute to the glucose-lowering effects of
YGB.43 However, in this study, improvements of glucose
omeostasis and a delay in diabetes onset were observed
ithout reductions of GIP responses.
In conclusion, we have demonstrated for the first time
hat IT surgery can delay the onset of diabetes in an
nimal model of type 2 diabetes. Factors that may be
nvolved in delaying diabetes onset include increases of
lasma bile acid concentrations and nutrient-stimulated
LP-17–36 secretion. Increases of circulating bile acid con-
entrations may have contributed to the increases of
LP-17–36 secretion and improvements of circulating lip-
ds. The increases of GLP-17–36 secretion probably con-
ributed to improvements of insulin sensitivity, islet
unction, and lipid metabolism. It would be of interest to
nvestigate why the onset of diabetes was only delayed
nd not prevented altogether after IT surgery. Adaptation
eg, down-regulation of GLP-1 production and secretion)
n the transposed segment of distal intestine could ac-
ount for this. Measurements of stimulated GLP-1 secre-
ion and GLP-1 expression in the transposed segment at
ater times after surgery would be informative in this
egard. Further studies of the effects of IT and other
ariatric surgical procedures in the UCD-T2DM ratodel will provide additional insight into the surgically
nduced improvements of metabolism and will identify
ew strategies for the prevention and treatment of type 2
iabetes.
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Note: To access the supplementary material
ccompanying this article, visit the online version of
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PY2R protein levels (B). Sham: n  10, ileal interposition (IT): n  10.
